Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025Clinical journal of oncology nursing

Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children’s Oncology Group

View Full Paper
Ask AI
Bookmark
Share

Authors

HKHolly R. KubaneyKMKathleen MontgomeryLGLauren Guidry

Discussion

Loading...

Member takes

Overview

Expert recommendations improve blinatumomab administration and safety in pediatric B-ALL, suggesting collaboration is key.

Key Points

  • Blinatumomab administration may enhance care for pediatric patients with B-ALL, addressing unique treatment challenges.
  • The recommendations emphasize monitoring for adverse events and improving transitions between inpatient and outpatient settings.
  • Implementation involved insights from pediatric oncology professionals and evidence from various institutions collaborating on best practices.
  • Commitment to tracking emerging trends in blinatumomab use can inform future standards of care for B-ALL patients.

Cite This Study

Kubaney et al. (2025) studied this question.

synapsesocial.com/papers/68c23595b210217d6477199ahttps://doi.org/10.1188/25.cjon.303-312
View Full Paper
Ask AI
Bookmark
Share